“And we remain on track for commercial approval of tevapadon in the US later this year.”

In context

“quential basis. The uptake is exceptionally strong across international markets, and we expect sales to ramp in the US, where Violet recently received full coverage. Feedback from prescribers and patients' communities remain very encouraging, highlighting meaningful improvements in on-time and off-time as a result of Violet's continuous 24-hour delivery and the control of symptoms morning, day, and night. Given these insights and the robust early launch trends globally, we now expect Violet to achieve blockbuster revenue in 2026. And when you add Tavapadon, for potential use as a monotherapy for early Parkinson's disease, as well as an adjunct to optimize oral therapy for more advanced patients, we believe we have the potential multibillion-dollar emerging PD franchise over the long term. And we remain on track for commercial approval of tevapadon in the US later this year. Moving now to oncology, where total revenues were nearly $1.7 billion in the quarter, down 2.5% on an operational basis. VENCLEXTA global sales were $710 million, up 6.4% on an operational basis, reflecting continued strong demand in CLL, with combination use of VENCLEXTA plus BTK inhibitors emerging as a preferred all-oral fixed-duration treatment. In 2026, we anticipate another major commercial catalyst with the global approvals of VENCLEXTA plus Calquence in combination, two leading brands in CLL, offering patients the potential for time off treatment, addressing an important need. Double-digit sales growth from Elijir, Epkinley, and Amrelis also helped to partially offset the expected sales decline for IMBRUVICA, which was down 20.8%, primarily due to continued competitive dynamics. A”